COMPASS Pathways plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- COMPASS Pathways plc is a biotechnology company focused on developing innovative mental health treatments, primarily by advancing the potential of psychedelics as medicines. The company’s main product is COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation designed for the treatment of mental health disorders. COMP360 is in advanced clinical development, including Phase III trials for treatment-resistant depression (TRD) and Phase II studies for conditions such as post-traumatic stress disorder (PTSD) and anorexia nervosa. The company also engages in research collaborations and development of scalable delivery models for its therapies. COMPASS Pathways operates primarily in the United Kingdom and the United States, with its headquarters located in London, UK. Founded in 2020, the company went public under the ticker CMPS and has positioned itself as a pioneer in evidence-based psychedelic mental health innovation. Recent developments include several strategic research collaboration agreements to optimize clinical delivery models for COMP360 if approved by regulators. Notably, in early 2024, COMPASS Pathways entered into a three-year research collaboration with Greenbrook TMS, a leading provider of transcranial magnetic stimulation services in the U.S., aiming to create scalable, cost-effective treatment delivery frameworks. In addition, a research partnership with Hackensack Meridian Health was established to develop clinical models for COMP360. The company has been advancing clinical trials and expanding indications for COMP360 beyond depression, focusing on mental health conditions with unmet therapeutic needs. It has also secured additional funding rounds to support ongoing research and development activities and continues to explore strategic partnerships to facilitate commercialization efforts and broaden patient access to its investigational treatments. COMPASS Pathways does not currently operate any owned manufacturing facilities but relies on contract manufacturing for drug production. Its business segments include clinical development, regulatory affairs, and commercialization readiness for its psychedelic therapy platform. The company targets patients with serious mental health disorders unresponsive to existing treatments, healthcare providers, and mental health clinics in markets across North America and Europe. The company’s innovative focus and recent operational activities position it as a notable player in the emerging psychedelic pharmaceutical industry, blending advanced biopharmaceutical development with strategic collaborations to accelerate mental health treatment solutions. COMPASS Pathways was formerly known as COMPASS Rx Limited before changing to its current name in 2020. Its pipeline and strategic orientation remain focused on advancing COMP360 through late-stage clinical development and preparing for potential regulatory approvals and market launches. This description reflects the company’s current business activities, core product offerings, and latest strategic developments as of 2025, based on the latest available information from its official communication and financial disclosures.
Company News
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
Compass Pathways Appoints Kelley Boucher as Chief People Officer
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Engineers Gate Manager LP Has $2.43 Million Position in Compass Pathways PLC Sponsored ADR $CMPS
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51
Compass Pathways stock rises as 52-week data show lasting depression relief